Calithera Biosciences reported that the company’s CANTATA clinical trial of telaglenastat in patients with advanced or metastatic renal cell carcinoma (RCC) failed to hit the primary endpoint.
https://www.pharmalive.com/wp-content/uploads/2021/01/Calithera-Cutting-Workforce-After-Kidney-Cancer-Study-Failure-BioSpace-1-4-21.jpeg350625Andrew Humphreyshttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngAndrew Humphreys2021-01-04 11:54:032021-01-04 17:47:27Calithera Cutting Workforce After Kidney Cancer Study Failure